DonaldsonMC. Hypercoagulable states in patients with peripheral vascular disease. In: WhittemoreAD, ed. Advances in Vascular Surgery. vol. 1. St. Louis, Mosby Year Book, 1993: 227–242.
2.
BellWRBilazarianSD. Coagulation, coagulation disorders, and antithrombotic therapy. In: YoungJRGraorRAOlinJW, eds. Peripheral Vascular Diseases. St. Louis, Mosby Year Book, 1991: 71–93.
3.
ClouseLHCompPB. The regulation of hemostasis: The protein C system. N Engl J Med1986; 314: 1298–1304.
4.
EsmonNLEsmonCT. Protein C and the endothelium. Semin Thromb Hemost1988; 14: 210–215.
5.
DonaldsonMCBelkinMWhittemoreAD. Impact of activated protein C resistance on general vascular surgical patients. J Vasc Surg1997; 25: 1054–1060.
6.
GriffinJHEvartBWidemanC. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood1993; 82: 1989–1993.
7.
DahlbackBCarlssonMSvenssonPJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A1993; 90: 1004–1008.
BertinaRMKoelemanBPKosterT. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature1994; 369: 64–67.
10.
ZollerBDahlbackB. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet1994; 343: 1536–1538.
11.
HalbmayerWMHaushoferASchonR. The prevalence of poor anticoagulant response to activated protein C among patients suffering from stroke or venous thrombosis and among healthy subjects. Blood Coagul Fibrinolysis1994; 5: 51–57.
12.
CushmanMBhushanFBovillE. Plasma resistance to activated protein C in venous and arterial thrombosis. (Letter) Thromb Haemost1994; 72: 647.
13.
OurielKGreenRMDeWeeseJA. Activated protein C resistance: Prevalence and implications in peripheral vascular disease. J Vasc Surg1996; 23: 46–52.
14.
DahlbackB. Resistance to activated protein C caused by the factor V R506 Q mutation is a common risk factor for venous thrombosis. Thromb Haemost1997; 78: 483–488.
15.
RidkerPMHennekensCHLindpaintnerK. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med1995; 332: 912–917.
16.
GriffinJHHeebMJSchwarzHP. Plasma protein S deficiency and thromboembolic disease. Prog Hematol1987; 15: 39–49.
17.
MarciniakEFarleyCGde SimonePA. Familial thrombosis due to antithrombin III deficiency. Blood1974; 43: 219–221.
18.
CosgriffTMBishopDTHershgoldFJ. Familial antithrombin III deficiency: Its natural history, genetics, diagnosis, and treatment. Medicine (Baltimore)1983; 62: 209–220.
19.
BauerKARosenbergRD. Role of antithrombin III as a regulator of in vivo coagulation. Semin Hematol1991; 28: 10–18.
20.
HughesGR. The antiphospholipid syndrome: Ten years on. Lancet1993; 342: 341–344.
21.
EsmonNLSmirnovMDEsmonCT. Lupus anticoagulants and thrombosis: The role of phospholipids. Haematologica1997; 82: 474–477.
22.
EsmonNLSmirnovMDEsmonCT. Thrombogenic mechanisms of antiphospholipid antibodies. Thromb Haemost1997; 78: 79–82.
23.
StrattaPCanaveseCFerreroS. Guidelines for looking at the antiphospholipid antibodies in systemic lupus erythematosus. Nephron1997; 76: 400–405.
24.
BazzanMTamponiGVaccarinoA. Natural and acquired inhibitors of hemostasis in selected outpatients with venous thromboembolic disease. Haematologica1997; 82: 420–422.
25.
CreaghMDMaliaRGCooperSM. Screening for lupus anticoagulant and anticardiolipin antibodies in women with fetal loss. J Clin Pathol1991; 44: 45–47.
PrietoLNSukiWN. Frequent hemodialysis graft thrombosis: Association with antiphospholipid antibodies. Am J Kidney Dis1994; 23: 587–590.
28.
HirshJFusterV. Guide to anticoagulant therapy. Part 1: Heparin. Circulation1994; 89: 1449–1468.
29.
HullRDRaskobGEHirshJ. Continuous intravenous heparin compared with subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med1986; 315: 1109–1114.
30.
PiniMPattaciniCQuintavallaR. Subcutaneous vs. intravenous heparin in the treatment of deep venous thrombosis: A randomized clinical trial. Thromb Haemost1992; 64: 222–226.
31.
GlazierRLCrowellEB. Randomized prospective trial of continuous vs. intermittent heparin therapy. JAMA1976; 236: 1365–1367.
32.
RobinsonAMMcLeanKAGreavesM. Subcutaneous vs. intravenous administration of heparin in the treatment of deep vein thrombosis: Which do patients prefer? A randomized crossover study. Postgrad Med J1993; 69(808): 115–167.
33.
KakkarVVBoecklOBoneuB. Efficacy and safety of a low molecular weight heparin and standard unfractionated heparin for prophylaxis of postoperative venous thromboembolism: European multicenter trial. World J Surg1997; 21: 2–9.
34.
HullRDRaskobGEPineoGF. Subcutaneous low molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis. N Engl J Med1992; 326: 975–982.
35.
MeyerGBrenotFPacouretG. Subcutaneous low molecular weight heparin Fragmin versus intravenous unfractionated heparin in the treatment of acute nonmassive pulmonary embolism: An open randomized pilot study. Thromb Haemost1995; 74: 1432–1435.
36.
LevineMGentMHirshJ. A comparison of low molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med1996; 334: 677–681.
37.
KearonC. Drug trials that have influenced our practice in the treatment of venous thromboembolism. Thromb Haemost1997; 78: 553–557.
38.
PiniMAielloSManottiC. Low molecular weight heparin versus warfarin in the prevention of recurrence after deep vein thrombosis. Thromb Haemost1994; 72: 191–197.
39.
SamamaCMGigouFPIII. Low molecular weight heparin versus unfractionated heparin in femorodistal reconstructive surgery: A multicentre open randomized study. Ann Vasc Surg1995; 9(Suppl): S45–S53.
40.
EdmonsonRACohenATDasSK. Low molecular weight heparin versus aspirin and dipyridamole after femoropopliteal bypass grafting. Lancet1994; 344: 914–918.
41.
HausbergMStoberKHeidenreichS. Arterial embolism and thrombocytopenia during heparin therapy. Schweiz Rundsch Med Prax1993; 82: 668–671.
42.
BentleyPGKakkarWScullyMF. An objective study of alternative methods of heparin administration. Thromb Res1980; 18: 177–187.
43.
MagnaniHN. Heparin-induced thrombocytopenia (HIT): An overview of 230 patients treated with orgaran. Thromb Hemost1993; 70: 554–561
44.
HirshJFusterV. Guide to anticoagulant therapy. Part 2: Oral anticoagulants. Circulation1994; 89: 1469–1480.
45.
PescatorePHorellouHM. Problems of oral anticoagulation in an adult with homozygous protein C deficiency and the late onset of thrombosis. Thromb Haemost1993; 69: 311–315.
46.
FennertyADolbenJPetalT. Flexible induction dose regimen for warfarin and prediction of maintenance dose. BMJ1984; 288: 1268–1270.
47.
ZauberNPStarkNW. Successful warfarin anticoagulation despite protein C deficiency and a history of warfarin necrosis. Ann Intern Med1986; 104: 659–660.
